

**Filed On Behalf Of:**

Novartis Pharmaceuticals Corporation

**By:**

Nicholas N. Kallas  
NKallas@fchs.com  
ZortressAfinitorIPR@fchs.com  
(212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

**BRECKENRIDGE PHARMACEUTICAL, INC,**  
Petitioner,

v.

**NOVARTIS PHARMACEUTICALS CORPORATION,**  
Patent Owner.

---

Case IPR2017-01592  
Patent 8,410,131

**PATENT OWNER'S UPDATED MANDATORY NOTICES  
UNDER 37 C.F.R. § 42.8(a)(3)**

Pursuant to the requirements of 37 C.F.R. § 42.8(a)(3), Novartis Pharmaceuticals Corporation (“Novartis” or “Patent Owner”) submits the following update to its June 30, 2017 Mandatory Notices (Paper No. 3).

**REAL PARTY-IN-INTEREST PURSUANT TO 37 C.F.R. § 42.8(b)(1)**

The real party-in-interest information has not changed.

**RELATED MATTERS PURSUANT TO 37 C.F.R. § 42.8(b)(2)**

U.S. Patent No. 8,410,131 (“the ’131 Patent”) has been or is at issue in the following judicial proceedings: (1) Novartis Pharm. Corp. et al. v. West-Ward Pharm. Int’l Ltd., No. 15-474-RGA (D. Del.) (final judgement that claims 1-3 of the ’131 Patent were not proven invalid by reason of obviousness entered on December 21, 2017); (2) Novartis Pharm. Corp. et al. v. West-Ward Pharm. Int’l Ltd., No. 18-1434 (Fed. Cir.) (appeal from No. 15-474-RGA (D. Del.) by West-Ward Pharm. Int’l Ltd.); (3) Novartis Pharm. Corp. et al. v. Breckenridge Pharm., Inc., No. 16-431-RGA (D. Del.); (4) Novartis Pharm. Corp. et al. v. Breckenridge Pharm., Inc., No. 17-420-RGA (D. Del.); and (5) Novartis Pharm. Corp. et al. v. Teva Pharm. USA, Inc., No. 17-393-RGA (D. Del.) (stipulation of dismissal entered on February 26, 2018).

The ’131 Patent is also the subject of the following Petition for *Inter Partes* Review: West-Ward Pharmaceuticals Int’l Ltd. v. Novartis Pharmaceuticals

Corporation, *Inter Partes* Review No. 2018-00507 (P.T.A.B.) (motion for joinder to *Inter Partes* Review No. 2017-01592 pending).

**IDENTIFICATION OF LEAD AND BACK-UP COUNSEL  
PURSUANT TO 37 C.F.R. §§ 42.8(b)(3) and 42.10**

The lead and back-up counsel information has not changed.

**SERVICE INFORMATION PURSUANT TO 37 C.F.R. § 42.8(b)(4)**

The service information has not changed.

Respectfully submitted,

Dated: March 19, 2018

/ Nicholas N. Kallas /  
Nicholas N. Kallas  
Registration No. 31,530  
Lead Counsel for Patent Owner  
FITZPATRICK, CELLA, HARPER  
& SCINTO  
1290 Avenue of the Americas  
New York, NY 10104-3800  
Tel. 212-218-2100

## CERTIFICATE OF SERVICE

I certify that a copy of Patent Owner's Updated Mandatory Notices Under 37 C.F.R. § 42.8(a)(3) was served on March 19, 2018 by causing it to be sent by email to counsel for Petitioner at the following email addresses:

Daniel R. Evans (devans@merchantgould.com)

Jeffrey D. Blake (jblake @merchantgould.com)

Melissa M. Hayworth (mhayworth@merchantgould.com)

Dated: March 19, 2018

/ Nicholas N. Kallas /

Nicholas N. Kallas

Registration No. 31,530

FITZPATRICK, CELLA, HARPER  
& SCINTO

1290 Avenue of the Americas

New York, NY 10104-3800

Tel. 212-218-2100